Pasithea Therapeutics Corp (KTTA NASDAQ) stock market data APIs
$1.1397
0.01(0.9%)
as of December 5, 2025
Try our APIs with
free plan!
Pasithea Therapeutics Corp Financial Data Overview
Price chart is built with
Anychart
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Prev. Close
1.1397
Open
1.1497
High
1.2192
Low
1.1283
52 wk Range
0.281-3.85
Market Cap
25 983 K
Shares Outstanding
22 399 K
Revenue
487 K
EPS
-0.66
Beta
0.214
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pasithea Therapeutics Corp data using free add-ons & libraries
Get Pasithea Therapeutics Corp Fundamental Data
Pasithea Therapeutics Corp Fundamental data includes:
- Net Revenue: 487 K
- EBITDA: -13 194 081
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pasithea Therapeutics Corp News
New
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Extends cash runway through at least the first half of 2028 Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investme...
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Village Farms Broke New Ground with Vape Launch in Quebec Organigram Announced Former BAT Strategy Chief as New CEO MTL Cannabis Posted Solid Second Quarter Results wit...
Pasithea Prices $60 Mln Offering To Advance PAS-004 And Broader Pipeline
(RTTNews) - Shares of Pasithea Therapeutics Corp. (KTTA) rose up to 38% after the company announced it has priced a $60 million public offering of 80 million shares of common stock at $0.75 per share....
US Equity Markets Close Higher During Thanksgiving Week as Interest Rate Cut Expectations Remain Strong
US equity indexes closed higher Friday despite a losing month amid broad market gains during the Tha PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
